The agenda includes:
Preparation of positions on the evaluation of drugs:
- Brukinsa (zanubrutinib) under the drug programme “Treatment of patients with Waldenström macroglobulinaemia (ICD-10: C88.0)”,
- Ofev (nintedanib) under the drug programme “Treatment with nintedanib for interstitial lung disease of progressive phenotype with fibrosis (PF ILD) (ICD-10 D86, J67.0-J67.9, J84.1, J84.8, J84.9, J99.0, J99.1)”,
- Beovu (brolucizumab) under the drug programme “Treatment of patients with retinal diseases (ICD-10: H35.3, H36.0) under Part B, i.e. treatment of patients with diabetic macular oedema (DME)”,
- Keytruda (pembrolizumab) under the drug programme B.9.FM. “Treatment of patients with breast cancer (ICD-10: C50)” – treatment of patients with breast cancer (mTNBC),
- Keytruda (pembrolizumab) under the drug programme „Treatment of patients with breast cancer (ICD-10: C50)” – treatment of patients with triple-negative breast cancer (eTNBC).
Preparation of an opinion on the inclusion in the reimbursement procedure of drugs containing the active substances:
- chloroquine for indications: autoimmune diseases other than those specified in the SmPC; porphyria cutanea tarda,
- metformin for the indication: insulin resistance syndromes in cases other than diabetes mellitus,
- venlafaxine for the indication: diabetic painful polyneuropathy.